Patient history 71 year old female patient, presents with LLE claudication (buttock, thigh and calf). Rutherford class 3 PMH: active smoker, HTN and HLD.

Slides:



Advertisements
Similar presentations
TAVOLA ROTONDA Quale Ruolo Clinico e Quale Rimborso per la Franctional Flow Reserve? Correlazioni anatomo-funzionali FFR vs IVUS Luigi Vignali, Parma Bologna.
Advertisements

Single Center Experience with Drug Eluting Stents for Infrapopliteal Occlusive Disease in Patients with Critical Limb Ischemia: Mid-term follow up Robert.
Andrew Bunney MD, PGY-4 University of Minnesota
Viabahn Covered Stents for Cephalic Arch Stenosis Can Improve Patency and Longevity of Upper Arm AV Fistulas Toufic Safa, MD, FACS Vascular & Endovascular.
Superficial Femoral Artery Stents - Bare, Covered, or Drug-Coated – “The Data and The HYPE” Dennis F. Bandyk, MD Division of Vascular & Endovascular Surgery.
Biondi-Zoccai: Peripheral interventions – metcardio.org Basic principles of peripheral interventions Giuseppe Biondi Zoccai University.
Evaluation of ReeKross balloon catheter in treating iliofemoral artery chronic total occlusions Xinwu Lu Vascular Center of Shanghai Jiaotong University.
Is There Still a Controversy About Stent Type for TASC C&D Lesions
Achieving Acute Success and Durable Results with Complete Total Occlusion? Christopher J. Kwolek, MD FACS Harvard Medical School Division of Vascular and.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
TOKUDA HOSPITAL SOFIA VASCULAR SURGERY AND ANGIOLOGY DEPARTMENT DR. A. DASKALOV, ASSOC. PROFF. V. CHERVENKOV.
D.DELEANU, M.CROITORU BUCHAREST, ROMANIA. BTK Interventions ? BTK disease = claudication and CLI BTK interventions = CLI Main goal of CLI therapy = functional.
FMRP 2014 | 1 Marc Bosiers Koen Deloose Joren Callaert A.Z. Sint-Blasius, Dendermonde Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist OLV Hospital,
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard
The Endocross Enabler-P: First in-Human Results
Intervention for Chronic Lower Extremity Venous Obstruction
Management of Aortic and Aortoiliac Stenoses and Occlusions
VISCERAL ARTERY STENTING in CHRONIC MESENTERIC ISCHEMIA (CMI)
New Stent Designs Applicable for Renal Intervention
Lutonix® Paclitaxel-Coated Balloon to Treat Obstructive Lesions in the Superficial Femoral and Popliteal Arteries Preliminary Six-Month Results from.
Rajesh Dave, MD, FACC, FSCAI Harrisburg, PA
Heavily calcified SFA lesions do not avoid the use of 4 F systems
James P. Zidar, M.D., F.A.C.C., F.S.C.A.I
Treatment of iliac vein obstruction
Stent Graft for the Treatment of ISR:
(DES)+BVS +DCB for long diffuse LAD disease
Aorta Infrarenal Stenosis: BE, SE or Covered Stents? CRT 2012
Crossing SFA-Popliteal Artery CTO’s
A.Z. Sint-Blasius, Dendermonde
How to do endovascular mechanical thrombaspiration
Eric J Dippel, MD FACC Davenport, Iowa, USA February 19, 2017
BVS Expand: First Results of Wide Clinical Applications
Medical Director of the Vascular Center
Instent Restenosis and Occlusion: Time for Surgical Revision?
Recanilization of Central Venous Total Occlusions
William A. Gray MD Director of Endovascular Services
OCT-Guided PCI What needs to be done to establish criteria?
Percutaneous Reconstruction of the Aortoiliac Bifurcation
Drug-Coated Balloons in Peripheral Artery Disease
Essesntials for CTO Recanalization
ALAA GABI, MD SUPERVISOR: MEHIAR EL-HAMDANI, MD
James P. Zidar, M.D., F.A.C.C., F.S.C.A.I
Circ Cardiovasc Interv
Andrew J. Klein, MD, FSCAI Piedmont Heart Institute, Atlanta, GA
Division of Endovascular Interventions
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
Giuseppe Biondi Zoccai
SKS Technique Clinical Case
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
Drug-Coated Balloons:
Technique of interventional repair in adult aortic coarctation
Division of Endovascular Interventions
Division of Endovascular Interventions Mount Sinai Hospital, NY
Division of Endovascular Interventions
Division of Endovascular Interventions
Technical aspects of repair of juxtarenal abdominal aortic aneurysms using the Zenith fenestrated endovascular stent graft  Gustavo S. Oderich, MD, Mateus.
Endovascular Live Case Mount Sinai Hospital, NY
Division of Endovascular Interventions
Division of Endovascular Interventions
Endovascular Live Case Mount Sinai Hospital, NY
Maintenance of Long-Term Clinical Benefit with
Division of Endovascular Interventions
Patient history Female, 71 y/o
The American College of Cardiology Presented by Dr. A. Abazid
History : Case April’ year old female patient with past medical history of presents with complaints of bilateral claudication in buttocks, hip.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Division of Endovascular Interventions
Presentation transcript:

Division of Endovascular Interventions Mount Sinai Hospital New York 07/31/2019

Patient history 71 year old female patient, presents with LLE claudication (buttock, thigh and calf). Rutherford class 3 PMH: active smoker, HTN and HLD. Medication: aspirin, atorvastatin, lisinopril.

Non-invasive Imaging CT-angiogram LE Arterial Duplex: Right: atherosclerotic plaque, no significant stenosis Left: atherosclerotic plaque with blunted wave forms suggestive of severe external  iliac disease. CT-angiogram

Iliac artery revascularization

Indication for revascularization ACC/AHA Guidelines Gerhard-Herman et al. JACC 2017;e71-126.

Appropriate use criteria Aorto-Iliac PVI Klein AJ et al. Catheter Cardiovasc Interv. 2017;90(4):E90-E110.

Appropriate use criteria Aorto-Iliac PVI Klein AJ et al. Catheter Cardiovasc Interv. 2017;90(4):E90-E110.

Technical considerations Access: Bilateral femoral artery Radial/brachial artery Angiographic views: contralateral oblique to better visualize the bifurcation (external and internal iliac artery) Sheath: minimum of 7Fr. Length 25cm Anticoagulation: preferred heparin, but bivalirudin is associated with similar outcomes*. ACT 250-275 * Sheikh, JACC int. 2009 vol 2; 871-876

Lesion crossing Non-occlusive lesion: Occlusive lesion: Hydrophilic-coated glide wire Angled support catheter Occlusive lesion: Hydrophilic coated and specialty wires (0.014 or 0.018) Microcatheter Exchange for more supportive 0.35 wire after crossing the lesion

Adjunctive crossing/re-entry devices for iliac CTO Crossing devices: Frontrunner, Viance, Ocelot Re-entry devices Outback, Offroad, Pioneer

Intravascular imaging IVUS: Calcium distribution MLA Vessel size JACC Intv 2015;8:1893–901

PTA: Important rules to follow Use initially nominally undersized balloon To avoid perforations, dissections To assess the degree of calcification Slow and sequential upsizing of balloons is recommended Avoid additional balloon expansion with onset of abdominal pain

Plaque modification: Cutting or scoring balloons are mainly used for cases of ISR Intravascular lithotripsy

Stent selection Self expanding stent (SE) Balloon expanding stents (BE) Covered stents SE BE

Pros and cons Device Advantages Disadvantages BE High radial strength (optimal for CIA, calcified lesion) Precise deployment Higher propensity of edge dissection/perforation Higher likelihood of plaque shift to the contralateral SE High flexibility Low risk of perforation Low radial strength Not suitable for precise deployment Cannot be post-dilated beyond their designated diameter Covered Excludes aneurysms Prevents neointimal growth in the stent lumen Excludes side branches Higher likelihood of edge restenosis

BE vs. SE ICE trial Inclusion criteria RF 1-4 single significant (>=70% diameter stenosis or occlusion by DUS) CIA or EIA lesion of 10-200 mm in length, not extending into the aorta or the common femoral artery. Comparison: BE (Visi-Pro, ev3 Endovascular, Inc., Plymouth, Minnesota) SE (Protege, ev3 Endovascular, Inc.) Primary endpoint: binary restenosis at 12 months (PSVR>=3.4 by DUS). Primary patency Freedom from TLR Independent predictors of restenosis JACC Intv 2017;10:1694–1704

Jaff MR. SCAI 2012. Las Vegas, NV MOBILITY: Modern Endovascular Management of Patients with Iliac Artery Disease PAD with high prevalence of calcification and multilevel disease SE: Absolute Pro vs. BE: Omnilink Elite stenting systems (Abbott Vascular, Santa Clara, CA). 9-Month Follow-up Absolute Pro (n = 151 pts, 181 lesions) Omnilink Elite (n = 153 pts, 203 lesions) Major Adverse Events 6.1% 5.4% Restenosis 8.4% 9.0% Freedom from TLR 97.1% 94.9% Functional improvements were noted in walking distance and speed as well as in stair climbing (P < 0.0001 for all endpoints vs. baseline). Jaff MR. SCAI 2012. Las Vegas, NV

Covered vs. non-covered stent COBEST trial Patients with aortoiliac occlusive disease - Inclusion criteria Men and women aged >18 years Informed consent obtained Evidence of TASC B, C, or D lesions Hemodynamically significant dissections and recurrent stenosis after angioplasty - Comparison: CS Advanta V12 balloon-expandable covered stent (Atrium Medical Corp, Hudson, NH) BE commercially available BMS - Primary endpoint: Freedom from binary restenosis (defined as >50% reduction in lumen diameter) or stent occlusion by DUS, CTA or DSA @ 18 months J Vasc Surg 2011;54:1561-70.

COBEST @ 18 months FUP J Vasc Surg 2011;54:1561-70.

COBEST @ 5-years FUP Primary patency Secondary patency Predictors of primary patency J Vasc Surg 2016;64:83-94.

Summary Endovascular iliac artery interventions are increasing including more complex lesions (TASC C and D) Careful case selection, work-up and planning is mandatory to achieve maximum success Despite the reported safety of bivalirudin, heparin is preferred AC Various stents are available for different lesion subsets with favorable long-term outcomes

Thank you